Holen Sie sich die Stockscreener-App
1.49
0.00%
0.00
Schlusskurs vom Vortag:
$1.49
Offen:
$1.49
24-Stunden-Volumen:
23,238
Relative Volume:
0.01
Marktkapitalisierung:
$4.94M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-8.34M
KGV:
-0.5785
EPS:
-2.5755
Netto-Cashflow:
$-7.71M
1W Leistung:
-5.70%
1M Leistung:
+118.89%
6M Leistung:
+15.50%
1J Leistung:
-40.64%
1-Tages-Spanne:
$1.49
$1.5895
1-Wochen-Bereich:
$1.47
$1.5895
52-Wochen-Spanne:
$0.575
$5.50
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Firmenname
Inmed Pharmaceuticals Inc
Sektor
Telefon
(604) 669-7207
Adresse
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.49 | 4.94M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Aktie (INM) Neueste Nachrichten
Current ratio of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Total revenue of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
MWG Stock Price and Chart — DUS:MWG - TradingView
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Valuation: PE, PB & Fair Value Analysis - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan
Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - TipRanks
InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView
Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com
InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo
InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK
InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan
InMed Pharmaceuticals (INM) Shares Slide Over 3% as Biotech Volatility IntensifiesInstitutional Flow Picks - newsline.com
InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate
InMed Pharmaceuticals (INM) Holds Near Support Amid Quiet Trading SessionShort Setup Alerts - newsline.com
INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals and Mentari Announce Merger AgreementThe Legal Advocate - The Legal Advocate
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²
Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter
InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus
Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.
Mentari, InMed Merge In Deal Backed By $290M Funding - Law360
Finanzdaten der Inmed Pharmaceuticals Inc-Aktie (INM)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):